Prostacyclin receptor
PTGIR | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||||||||||||||||||||||||||||||
Wikidata | ||||||||||||||||||||||||||||||||||||||||
|
The Prostacyclin receptor, also termed the prostaglandin I2 receptor or just IP, is a receptor belonging to the prostaglandin (PG) group of receptors. IP binds to and mediates the biological actions of prostacyclin (also termed Prostaglandin I2, PGI2, or when used as a drug, epoprostenol). IP is encoded in humans by the PTGIR gene. While possessing many functions as defined in animal model studies, the major clinical relevancy of IP is as a powerful vasodilator: stimulators of IP are used to treat severe and even life-threatening diseases involving pathological vasoconstriction.
Gene
The PTGIR gene is located on human chromosome 19 at position q13.32 (i.e. 19q13.32), contains 6 exons, and codes for a
Expression
IP is most highly expressed in brain and thymus and is readily detected in most other tissues. It is found throughout the vascular network on endothelium and smooth muscle cells.[5][6]
Ligands
Activating ligands
Standard
Inhibiting ligands
Several synthetic compounds bind to, but do not activate, IP and thereby inhibit its activation by the activating ligands just described. These
Mechanism of cell activation
IP is classified as a relaxant type of prostenoid receptor based on its ability, upon activation, to relax certain pre-contracted smooth muscle preparations and smooth muscle-containing tissues such as those of pulmonary arteries and veins.
Functions
Studies using animals genetically engineered to lack IP and examining the actions of EP4 receptor agonists in animals as well as animal and human tissues indicate that this receptor serves various functions. It has been regarded as the most successful therapeutic target among the 9 prostanoid receptors.[10]
Platelets
IP
Cardiovascular system
IP activation stimulates the dilation of arteries and veins in various animal models as well as in humans. It increases the blood flow through, for example, the pulmonary, coronary, retinal and
IP activators inhibit the adherence of circulating platelets and leukocytes adherence to vascular endothelium thereby blocking their entry into sites of tissue disturbance. The activators also inhibit vascular smooth muscle cells from proliferation by blocking these cells' growth cycle and triggering their apoptosis (i.e. cell death). These actions, along with its anti-inflammatory effects, may underlie the ability of IP gene knockout in an ApoE(−/−) mouse model to cause an accelerated rate of developing atherosclerosis.[7] [10]
Inflammation
Mouse studies indicate that the PGI2-IP axis activates cellular signaling pathways that tend to suppress allergic inflammation. The axis inhibits bone marrow-derived
In human studies, PGI2 failed to alter bronchoconstriction responses to allergen but did protect against exercise-induced and ultrasonic water-induced bronchoconstriction in asthmatic patients. It also caused bronchodilation in two asthmatic patients. However, these studies were done before the availability of potent and selective IP agonists. These agonists might produce more effective inhibitor results on airways allergic diseases but their toxicity (e.g. pulmonary edema, hypotension) has tended to restrict there study in asthmatic patients.[6]
IP receptors also appear involved in suppressing non-allergic inflammatory responses. IP receptor-deficient mice exhibit a reduction in the extent and progression of inflammation in a model of collagen-induced arthritis. This effect may result from regulating the expression of arthritis-related, pro-inflammatory genes (i.e. those for
Pain perception
IP(-/-) mice exhibit little or no writhing responses in an acetic acid-induced pain model. The mouse IP receptor also appears to be involved in the development of heat-induced
Clinical significance
Toxicity
IP receptor agonists, particularly when used intravenously, have been associated with the rapid development of pulmonary edema, hypotension, bleeding due to inhibition of platelet aggregation, and tachycardia.
Vasoconstriction
IP receptor agonists are front-line drugs to treat
Thrombotic diseases
IP receptor agonists have been used to treat Thromboangiitis obliterans, a disease involving blood clotting and inflammation of the small and medium-sized arteries and veins in the hands and feet.[23]
Genomic studies
An adenine (A) to cytosine (C)
See also
- PTGIR gene (https://www.wikigenes.org/e/gene/e/5739.html)
- PGI2
- Prostaglandin receptors
- Eicosanoid receptor
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000160013 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000043017 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ a b "PTGIR prostaglandin I2 receptor [Homo sapiens (Human)] - Gene - NCBI".
- ^ PMID 25541289.
- ^ PMID 21508345.
- ^ S2CID 207058745.
- PMID 18946232.
- ^ PMID 21752876.
- S2CID 1513449.
- PMID 26980701.
- S2CID 7766467.
- S2CID 26734051.
- ^ PMID 23850788.
- ^ S2CID 20499189.
- ^ S2CID 19698203.
- PMID 26825901.
- PMID 28096285.
- PMID 25673314.
- PMID 28018840.
- PMID 26516035.
- PMID 32364620.
- PMID 27708579.
- S2CID 29436581.
- PMID 27990118.
Further reading
- Coleman RA, Smith WL, Narumiya S (June 1994). "International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes". Pharmacological Reviews. 46 (2): 205–29. PMID 7938166.
- Rauvala H, Peng HB (June 1997). "HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts". Progress in Neurobiology. 52 (2): 127–44. S2CID 38987199.
- Smyth EM, FitzGerald GA (2003). Human prostacyclin receptor. Vitamins & Hormones. Vol. 65. pp. 149–65. PMID 12481546.
- Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M (April 1994). "Cloning and expression of a cDNA for the human prostanoid IP receptor". The Journal of Biological Chemistry. 269 (16): 12173–8. PMID 7512962.
- Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, Ichikawa A (May 1994). "Cloning and expression of a cDNA for the human prostacyclin receptor". FEBS Letters. 344 (1): 74–8. S2CID 12203377.
- Ogawa Y, Tanaka I, Inoue M, Yoshitake Y, Isse N, Nakagawa O, Usui T, Itoh H, Yoshimasa T, Narumiya S (May 1995). "Structural organization and chromosomal assignment of the human prostacyclin receptor gene". Genomics. 27 (1): 142–8. PMID 7665161.
- Duncan AM, Anderson LL, Funk CD, Abramovitz M, Adam M (February 1995). "Chromosomal localization of the human prostanoid receptor gene family". Genomics. 25 (3): 740–2. PMID 7759114.
- Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K (October 1994). "Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system". Circulation. 90 (4): 1643–7. PMID 7923647.
- Bonaldo MF, Lennon G, Soares MB (September 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research. 6 (9): 791–806. PMID 8889548.
- Sasaki Y, Takahashi T, Tanaka I, Nakamura K, Okuno Y, Nakagawa O, Narumiya S, Nakao K (August 1997). "Expression of prostacyclin receptor in human megakaryocytes". Blood. 90 (3): 1039–46. PMID 9242534.
- Fisch A, Tobusch K, Veit K, Meyer J, Darius H (August 1997). "Prostacyclin receptor desensitization is a reversible phenomenon in human platelets". Circulation. 96 (3): 756–60. PMID 9264479.
- Smyth EM, Li WH, FitzGerald GA (September 1998). "Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c". The Journal of Biological Chemistry. 273 (36): 23258–66. PMID 9722557.
- Kömhoff M, Lesener B, Nakao K, Seyberth HW, Nüsing RM (December 1998). "Localization of the prostacyclin receptor in human kidney". Kidney International. 54 (6): 1899–908. PMID 9853255.
- Hayes JS, Lawler OA, Walsh MT, Kinsella BT (August 1999). "The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling". The Journal of Biological Chemistry. 274 (34): 23707–18. PMID 10446129.
- Smyth EM, Austin SC, Reilly MP, FitzGerald GA (October 2000). "Internalization and sequestration of the human prostacyclin receptor". The Journal of Biological Chemistry. 275 (41): 32037–45. PMID 10889200.
- Lawler OA, Miggin SM, Kinsella BT (September 2001). "Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling". The Journal of Biological Chemistry. 276 (36): 33596–607. PMID 11443126.
- Zhang Z, Austin SC, Smyth EM (September 2001). "Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction". Molecular Pharmacology. 60 (3): 480–7. PMID 11502878.
- Fortier I, Patry C, Lora M, Samadfan R, de Brum-Fernandes AJ (August 2001). "Immunohistochemical localization of the prostacyclin receptor (IP) human bone". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 65 (2): 79–83. PMID 11545623.
External links
- "Prostanoid Receptors: IP1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09.
- Overview of all the structural information available in the PDB for UniProt: P43252 (Mouse Prostacyclin receptor) at the PDBe-KB.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.